Moderna, Inc. Defined Contribution Plan, Cost
Moderna, Inc. (MRNA) reported Defined Contribution Plan, Cost of $20.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2023-02-24
- Moderna, Inc. defined contribution plan, cost for fiscal 2022 was $20.00M, a 100.00% increase from fiscal 2021.
- Moderna, Inc. defined contribution plan, cost for fiscal 2021 was $10.00M, a 100.00% increase from fiscal 2020.
- Moderna, Inc. defined contribution plan, cost for fiscal 2020 was $5.00M, a 25.00% increase from fiscal 2019.
- Moderna, Inc. defined contribution plan, cost for fiscal 2019 was $4.00M, a 90.48% increase from fiscal 2018.
| Period end | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|
| 2022-12-31 | $20.00M 10-K · filed 2023-02-24 | |
| 2021-12-31 | $10.00M 10-K · filed 2023-02-24 | $18.00M 10-K · filed 2022-02-25 |
| 2020-12-31 | $5.00M 10-K · filed 2023-02-24 | |
| 2019-12-31 | $4.00M 10-K · filed 2022-02-25 | $4.20M 10-K · filed 2020-02-27 |
| 2018-12-31 | $2.10M 10-K · filed 2021-02-26 | |
| 2017-12-31 | $2.10M 10-K · filed 2020-02-27 | |
| 2016-12-31 | $1.20M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |